Healthcare Global Enterprises · NSE: HCG · BSE: 539787
Q4 FY21 results · Jan–Mar 2021
Healthcare Global Enterprises reported revenue from operations of ₹298.05 crore (up 10.2% from Q4 FY20) and net loss of ₹113.76 crore for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 298.05 | 270.37 | +10.2% | 274.01 | +8.8% |
| Other income | 4.40 | 1.69 | +160.4% | 5.82 | −24.4% |
| Total income | 302.45 | 272.06 | +11.2% | 279.83 | +8.1% |
| Profit before share of associates & JVs and tax | (105.23) | (40.14) | Loss widened | (35.63) | Loss widened |
| Share of profit/(loss) of associates & JVs | 0.88 | (1.54) | 0.24 | ||
| Net profit for the period | (113.76) | (50.44) | Loss widened | (34.73) | Loss widened |
| Attributable to shareholders of the company | (102.17) | (43.58) | Loss widened | (29.25) | Loss widened |
| EPS, basic (₹) | (8.14) | (4.91) | not comparable | (2.33) | Loss widened |
| Net margin (%) | -38.2 | -18.7 | -12.7 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 179.51 | 171.99 | +4.4% | 164.06 | +9.4% |
| Other income | 4.60 | 2.92 | +57.5% | 8.28 | −44.4% |
| Total income | 184.11 | 174.91 | +5.3% | 172.34 | +6.8% |
| Profit before tax | (150.66) | (49.49) | Loss widened | (13.83) | Loss widened |
| Net profit for the period | (153.22) | (43.55) | Loss widened | (13.01) | Loss widened |
| EPS, basic (₹) | (12.20) | (4.91) | not comparable | (1.04) | Loss widened |
| Net margin (%) | -85.4 | -25.3 | -7.9 |
Consolidated
- Filed with BSE
- 18 Jun 2021, 08:22 IST
- Board meeting
- 17 Jun 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 Jun 2021, 08:22 IST
- Board meeting
- 17 Jun 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE